Literature DB >> 22094257

Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis.

Charbel Darido1, Smitha R Georgy, Tomasz Wilanowski, Sebastian Dworkin, Alana Auden, Quan Zhao, Gerhard Rank, Seema Srivastava, Moira J Finlay, Anthony T Papenfuss, Pier Paolo Pandolfi, Richard B Pearson, Stephen M Jane.   

Abstract

Despite its prevalence, the molecular basis of squamous cell carcinoma (SCC) remains poorly understood. Here, we identify the developmental transcription factor Grhl3 as a potent tumor suppressor of SCC in mice, and demonstrate that targeting of Grhl3 by a miR-21-dependent proto-oncogenic network underpins SCC in humans. Deletion of Grhl3 in adult epidermis evokes loss of expression of PTEN, a direct GRHL3 target, resulting in aggressive SCC induced by activation of PI3K/AKT/mTOR signaling. Restoration of Pten expression completely abrogates SCC formation. Reduced levels of GRHL3 and PTEN are evident in human skin, and head and neck SCC, associated with increased expression of miR-21, which targets both tumor suppressors. Our data define the GRHL3-PTEN axis as a critical tumor suppressor pathway in SCC. 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094257     DOI: 10.1016/j.ccr.2011.10.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  106 in total

Review 1.  The duality of oncomiR addiction in the maintenance and treatment of cancer.

Authors:  Christopher J Cheng; Frank J Slack
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

2.  Clinical significance of GRHL3 expression in diffuse large B cell lymphoma.

Authors:  Wei Liu; Minwen Ha; Xiaodong Wang; Nanchang Yin
Journal:  Tumour Biol       Date:  2016-01-22

3.  A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Naval Daver; Yanis Boumber; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes; Michael E Rytting; Jitesh D Kawedia; Jordan Basnett; Kirk S Culotta; Zhihong Zeng; Hongbo Lu; Mary Ann Richie; Rebecca Garris; Lianchun Xiao; Wenbin Liu; Keith A Baggerly; Elias Jabbour; Susan O'Brien; Jan Burger; Linda J Bendall; Deborah Thomas; Marina Konopleva
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

Review 4.  Roles of Grainyhead-like transcription factors in cancer.

Authors:  S M Frisch; J C Farris; P M Pifer
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

5.  The Grainyhead transcription factor Grhl3/Get1 suppresses miR-21 expression and tumorigenesis in skin: modulation of the miR-21 target MSH2 by RNA-binding protein DND1.

Authors:  A Bhandari; W Gordon; D Dizon; A S Hopkin; E Gordon; Z Yu; B Andersen
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

6.  The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.

Authors:  M Fragni; S A Bonini; P Bettinsoli; S Bodei; D Generali; A Bottini; P F Spano; M Memo; S Sigala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-02-24       Impact factor: 3.000

Review 7.  The microRNA networks of TGFβ signaling in cancer.

Authors:  V P Sivadas; S Kannan
Journal:  Tumour Biol       Date:  2013-12-10

8.  Pten loss induces autocrine FGF signaling to promote skin tumorigenesis.

Authors:  Kristina Hertzler-Schaefer; Grinu Mathew; Ally-Khan Somani; Sunil Tholpady; Madhavi P Kadakia; Yiping Chen; Dan F Spandau; Xin Zhang
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

9.  Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Authors:  Xiaodong Ma; Saibyasachi N Choudhury; Xiang Hua; Zhongping Dai; Yong Li
Journal:  Carcinogenesis       Date:  2013-02-05       Impact factor: 4.944

10.  Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21(∗) in SCC progression.

Authors:  Yejing Ge; Liang Zhang; Maria Nikolova; Boris Reva; Elaine Fuchs
Journal:  Nat Cell Biol       Date:  2015-11-30       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.